Breaking News

IDIFARMA Gains Authorization for New Dosage Forms

By Kristin Brooks | January 13, 2014

Expanded GMP capabilities include powders, tablets, and hard capsules

IDIFARMA has obtained an extension of its authorization as a GMP clinical manufacturer by the Spanish Medicines Agency (AEMPS) to include new dosage forms. The expanded GMP capabilities allow for the manufacture of powders for oral use (including powders for oral solutions and suspensions), as well as tablets and hard capsules. IDIFARMA has also adapted its lab authorization to the new European format for manufacturing, including GMP over-encapsulation to blind solid dosage forms for double-blind trials.
The company is also GMP-certified to provide primary and secondary packaging services, quality control testing and QP release, storage, shipment and destruction of medication, as well as services such as blinding strategies, placebo manufacturing, stability studies, and regulatory affairs. IDIFARMA’s high containment development and manufacturing facilities are authorized to handle high potency compounds, as well as humidity-controlled conditions with organic or water solvents.

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks